Company news
Tibet Rhodiola Pharmaceutical Holding Co. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(600211)"Tibet Rhodiola Pharmaceutical Holding Co., Ltd."Announcement on Progress in Repurchasing Shares
November 3, 2026
(600211)"Tibet Rhodiola Pharmaceutical Holding Co., Ltd."Announcement on Obtaining U.S. FDA Clinical Trial Approval for ART002g1 Injection by Controlled Subsidiary
October 16, 2026
(600211)"Tibet Rhodiola Pharmaceutical Holding Co., Ltd."Announcement on Release of Pledge of Certain Shares Held by Shareholder Holding More Than 5% of the Shares
October 8, 2026
(600211)"Tibet Rhodiola Pharmaceutical Holding Co., Ltd."Announcement on Progress in Repurchasing Shares
October 8, 2026
Announcement on Implementation of Dividend Distribution for the First Half of 2026
September 6, 2026
Announcement on Outline of the 2026 Semi-annual Performance Briefing
September 1, 2026
Announcement on Convening the 2026 Semi-annual Performance Briefing
August 24, 2026
Announcement on Resolutions of the 2nd Meeting of the 9th Board of Directors
August 13, 2026
Announcement on Progress in Providing Guarantee for Controlled Subsidiary
July 15, 2026
Announcement on Progress in Share Repurchase
July 1, 2026
Announcement on Release of Pledge of Some Shares Held by Shareholders with Over 5% Shares
June 4, 2026
Announcement on Progress in Share Repurchase
June 1, 2026
Announcement on Implementation of Dividend Distribution for 2025
May 14, 2026
Announcement on Resolutions of the 1st Meeting of the 9th Board of Directors
May 8, 2026
Announcement on Resolutions of the 13th Meeting of the 8th Board of Directors
April 28, 2026
Announcement on Extension of Pledge of Shares Held by Shareholders with Over 5% Shares
April 16, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
April 13, 2026
Announcement on Outline of the 2025 Annual Performance Briefing
April 8, 2026
Indicative Announcement on Convening the 2025 Annual General Meeting
April 6, 2026
Announcement on Adding Provisional Proposal at 2025 Annual General Meeting
March 30, 2026
Announcement on Renewing Engagement of Accounting Firm
March 12, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
February 25, 2026
Indicative Announcement on Convening the 1st Extraordinary General Meeting in 2026
February 11, 2026
Announcement on Providing Guarantee for Holding Subsidiary
February 5, 2026
Announcement on Progress in Share Repurchase Reaching 1%
January 20, 2026
Announcement on Progress in Providing Guarantee for Holding Subsidiary
January 7, 2026
Announcement on Initially Repurchasing Shares
January 5, 2026
Announcement on Shareholding of Top 10 Shareholders and Top 10 Holders of Shares Without Sales Limit Concerning Shares Repurchase
December 24, 2025
Plan for Repurchasing Shares through Call Auction
December 18, 2025
Announcement on the Continued Inclusion of the Company’s Product Xinhuaosu in the National Medical Insurance Drug Catalog
December 8, 2025
Announcement on Outline of the Q3 2025 Performance Briefing
December 3, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 26, 2025
Announcement on Resolutions of the 11th Meeting of the 8th Board of Directors
October 30, 2025
Announcement on Outline of the 2025 Semi-annual Performance Briefing
October 10, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
September 24, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
September 15, 2025
Indicative Announcement on Convening the 2nd Extraordinary General Meeting in 2025
September 8, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
September 2, 2025
Notice on Convening the 2nd Extraordinary General Meeting in 2025
August 27, 2025
Indicative Announcement on Convening the 1st Extraordinary General Meeting in 2025
August 25, 2025
Notice on Convening the 1st Extraordinary General Meeting in 2025
August 15, 2025
Announcement on Progress in Providing Guarantee for Wholly-owned Subsidiary
May 19, 2025
Announcement on Obtaining Approval Notice for Drug Supplement Application by Wholly-Owned Subsidiary
May 16, 2025
Report for Q1 2025
April 28, 2025
Announcement on Convening the 2024 Annual Performance Briefing
April 15, 2025
Announcement on Resolution of the 2024 Annual General Meeting
April 8, 2025
Indicative Announcement on Convening the Annual General Meeting in 2024
March 28, 2025
Announcement on 2024 Annual Profit Distribution Plan
March 14, 2025
Announcement on the Implementation of Q3 2024 Dividend Distribution
January 10, 2025
Announcement on the Profit Distribution Plan for Q3 2024
December 30, 2024